Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)

Enrolling by invitation

Conditions studied: Multiple Myeloma

In brief

The PROMISE Study aims to establish a prospective cohort of individuals with precursor conditions to multiple myeloma, such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). We will study these patients as a means to identify risk factors for progression to symptomatic multiple myeloma.

Key facts

Study ID
NCT03689595
Run by
Dana-Farber Cancer Institute
People needed
30000
Starts
2018-10-31
Expected to finish
2033-10-31
Last updated by the study team
2026-07-31

Who can join

Age: 30 and older. Sex: any. Healthy volunteers: accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.